Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases
Shots:
- Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research- development- regulatory and commercial milestones along with royalties on sales of small molecules
- The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global commercialization
- The R&D collaboration builds on Lead Pharma's expertise in the discovery- design- and optimization of small-molecule treatments
Ref: PRNewswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com